The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to procure an Agilent Technologies, Inc 5200 Fragment Analyzer Instrument, along with a computer and monitor, on a sole source basis. This acquisition aims to replace the discontinued Agilent 2100 Bioanalyzer, providing enhanced performance, scalability, and workflow efficiency for the Department of Transfusion Medicine (DTM). The new system is critical for accurate assessment of DNA, RNA, and NGS library preparations, which are essential for ongoing research studies. Interested parties capable of providing similar products may submit a capability statement to Emeka Onyejekwe at emeka.onyejekwe@nih.gov by July 19, 2025, at noon EST for consideration.